ResMed (NYSE:RMD) Azioni

ResMed

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

ResMed Inc

Remedy Entertainment PLC

Richmond Minerals Inc

RICHMOND MINERALS INC by Richmond Minerals Inc.

During the last three months, 6 analysts shared their evaluations of ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated ResMed and provided 12-month price targets. The average target is $261.33, accompanied by a high estimate of $286.00 and a low estimate of $240.00. This upward trend is apparent, with the current average reflecting a 0.71% increase from the previous average price target of $259.50.
<img src="https://www.benzinga.com/files/images/story/2025/1741204865_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive ResMed is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$240.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>David Low</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$286.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$266.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$260.00</td>
<td>$252.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$252.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Announces</td>
<td>Hold</td>
<td>$250.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ResMed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ResMed compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of ResMed's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of ResMed's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RMD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ResMed analyst ratings.</a>
<h2>Unveiling the Story Behind ResMed</h2>
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
<h3>Financial Insights: ResMed</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: ResMed's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 10.26%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ResMed's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 26.88%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): ResMed's ROE excels beyond industry benchmarks, reaching 6.6%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ResMed's ROA excels beyond industry benchmarks, reaching 4.8%. This signifies efficient management of assets and strong financial health.
Debt Management: ResMed's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.16.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Beyond The Numbers: 6 Analysts Discuss ResMed Stock

Citigroup analyst Mathieu Chevrier upgrades ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) from Neutral to Buy.

News

Upgrades

Citigroup Upgrades ResMed to Buy

WIIM

ResMed shares are trading lower after Stifel cut its price target on the stock from $250 to $240.

Stifel analyst Jonathan Block maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Hold and lowers the price target from $250 to $240.

Price Target

Stifel Maintains Hold on ResMed, Lowers Price Target to $240

ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) has outperformed the market over the past 10 years by 2.93% on an annualized basis producing an average annual return of 13.86%. Currently, ResMed has a market capitalization of $34.51 billion. 
Buying $1000 In RMD: If an investor had bought $1000 of RMD stock 10 years ago, it would be worth $3,648.09 today based on a price of $235.00 for RMD at the time of writing.
<h3>ResMed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740580209_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In ResMed 10 Years Ago Would Be Worth Today

Shares of SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) are making a nice move higher Tuesday. Some analysts believe that this is due to a report that suggests institutions make up more than 30% of the company's ownership.
Despite the move, the stock is trading within a well-defined range. This means there may be opportunities for low-risk trades. This is why it is our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.
There are generally two ways that traders can profit from rangebound stocks. 
The first is to sell close to the top of the range and to buy near the bottom of the range.<a href="https://www.benzinga.com/general/health-care/25/02/43443605/stock-of-the-day-trading-the-range-in-resmed"> Yesterday's Stock of the Day covered this strategy </a>with ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>).
At the top of a range, there is resistance, and sometimes stocks sell off when they hit resistance. At the bottom of the range, there is support, and sometimes stocks rally after they hit this support.
There is also another way to trade a range. This involves trading a breakout or breakdown. See below.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="546" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04134953/111-1024x546.png" alt="" class="wp-image-765507" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04134953/111-1024x546.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04134953/111-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04134953/111-768x409.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04134953/111.png 1522w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43469234/trump-prepares-maximum-pressure-on-iran-oil-jumps-above-73-energy-stocks-rally">Trump Prepares Maximum Pressure On Iran: Oil Jumps Above $73, Energy Stocks Rally</a>
Resistance is a large concentration of stocks that are for sale at, or close to, the same price. Sometimes stocks sell off of resistance because people who wish to sell start to undercut each other. The buyers will go to whoever is willing to sell at the lowest price and they don't want to miss their trade.
But sometimes, the buyers overpower the sellers and push the stock through the resistance. This is called a ‘breakout'. These tend to be bullish dynamics. It shows that the people who created the resistance are out of the market. They have either canceled or finished their orders.
With these sellers gone, people who wish to buy will need to be willing to pay premiums and this could force the stock into a new uptrend. This is why some traders buy stocks that are breaking out.
Support is a large concentration of buyers willing to pay the same or close to the same price for new shares. Sometimes, stocks rally off support when buyers start to outbid each other. This could result in a snowball effect that forces the price higher.
But sometimes, the sellers overpower the buyers and push the stock below the support. This is called a ‘breakdown'. &nbsp;This tends to be bearish because it shows that the investors and traders who created the support have left the market.
Sellers may be forced to push the price lower to get the attention of buyers. This could form a new downtrend. This is why some traders sell when breakdowns occur.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports/25/02/43473207/disney-q1-earnings-preview-can-moana-2-mufasa-the-lion-king-help-continue-streak-of-analyst-beats">Disney Q1 Earnings Preview: Can &#8216;Moana 2,&#8217; &#8216;Mufasa: The Lion King&#8217; Help Continue Streak Of Analyst Beats?</a></li>
</ul>
Image: Shutterstock

Technicals

SOUN

Stock Of The Day: Different Ways To Profit From SoundHound

ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) shares are consolidating on Monday. This follows Friday's decline of more than 8%. The sell-off was driven by a disappointing <a href="https://www.benzinga.com/quote/RMD/analyst-ratings">earnings report</a>.
Traders are waiting to see if ResMed drops to levels around $228.80. This is a support level and sometimes when a stock hits support, a reversal and move higher follows. As you can see on the chart, this happened the last time ResMed dropped to this price. This is why it's our Stock of the Day.
It may happen again. When a stock has been in a defined trading range, some traders like to sell if the shares reach the top of the range. Some like to buy at the bottom of the range.
The top of a range is called resistance. It is a price level where there is a large amount of sell interest. If a market is trending higher, there are more shares to be bought than there are to be sold.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="545" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03124759/ResMed.120251-1024x545.png" alt="" class="wp-image-763134" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03124759/ResMed.120251-1024x545.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03124759/ResMed.120251-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03124759/ResMed.120251-768x409.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03124759/ResMed.120251.png 1527w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43439189/robinhood-to-offer-super-bowl-event-contracts">Robinhood To Offer Super Bowl Event Contracts</a>
Buyers have to be willing to outbid others if they want to acquire shares.&nbsp;This forces it into an uptrend. When a stock reaches resistance, there are more than enough sell orders to fill all of the buy orders, so the uptrend ends.
Sometimes, stocks reverse and head lower after reaching resistance. This happened the last two times ResMed hit the resistance around $258. Anxious sellers undercut each other and it resulted in a snowball effect that pushed the price down.
Stocks can rally after they reach support. Support is a price level or range with large amounts of buy interest.
Sometimes, when a stock is close to support, some investors and traders who created the support get nervous. They know sellers will go to whoever wants to pay the highest price. They don't want to miss the trade, so they increase the prices they are willing to pay.
Other nervous buyers see this and do the same. It can result in a bidding war that forces the price up.
As you can see on the chart, this happened the last three times <a href="https://www.benzinga.com/quote/RMD">ResMed</a> reached support around $228.80. It may be about to happen again.
Read Next: • <a href="https://www.benzinga.com/25/02/43439462/us-manufacturing-confidence-tops-forecasts">US Manufacturing Confidence Tops Forecasts, Yet Price Pressures Intensify, &#8216;Could Become A Concern,&#8217; Economist Says</a>

Photo: Shutterstock

Health Care

Stock Of The Day: Trading The Range In ResMed

JP Morgan analyst David Low maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Overweight and raises the price target from $270 to $286.

JP Morgan Maintains Overweight on ResMed, Raises Price Target to $286

Major stock indices have completed their recovery following Monday's sharp drop, buoyed by tech stocks rallying on the back of solid earnings <a href="https://www.benzinga.com/news/econ-s">and positive macroeconomic data.</a>
The S&amp;P 500 index stands at 6,118 points at midday trading in New York, not far from the all-time high of 6,128 points reached last Friday.
The Personal Consumption Expenditure price index — the Fed's preferred inflation gauge — <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43390001/feds-favorite-inflation-gauge-rises-as-predicted-consumer-spending-jumps-at-fastest-pace-in-9-months">came in line with expectations in December</a>, easing market participants&#8217; concerns over interest rates. Fed futures continue to reflect expectations for two rate cuts by the end of the year.
Meanwhile, personal spending posted a robust 0.7% increase in December, signaling strong consumer appetite in the final month of the year — a promising sign for corporate earnings.
The Magnificent Seven — as tracked by the Roundhill Magnificent Seven ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NASDAQ">MAGS</a>) – soared 1.6% on Friday, effectively erasing weekly losses after plunging as much as 3.1% on Monday due to the DeepSeek selloff.
Yet, within the elite group, NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) remains 12% lower than last Friday's close, with Friday&#8217;s gains primarily driven by Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)
The Dow Jones, flat on the day, attempted to break its all-time highs at the open but faced resistance from sellers. Sector-wise, tech leads the charge, while energy lags following mixed earnings results from oil giants Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>).
Gold climbed above $2,800 per ounce, extending new records as demand for the ultimate safe-haven asset surges amid rising geopolitical and trade risks. This comes after President Donald Trump confirmed on Thursday his plan to introduce 25% tariffs on Mexico and Canada starting Feb. 1.
WTI crude oil prices were down 0.3% at $72.3 per barrel, potentially marking their second consecutive weekly decline.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) paused for a breather, holding steady at $104,800.
<h1 class="wp-block-heading">Friday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>• Nasdaq 100</td>
<td>21,814.96</td>
<td>1.4%</td>
</tr>
<tr>
<td>• S&amp;P 500</td>
<td>6,118.40</td>
<td>0.8%</td>
</tr>
<tr>
<td>• Russell 2000</td>
<td>2,315.94</td>
<td>0.4%</td>
</tr>
<tr>
<td>• Dow Jones</td>
<td>44,973.98</td>
<td>0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:24 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent013125&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;rose 0.7% to $609.38.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) edged up by 0.1% to $449.30.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rallied 1.4% to $530.49.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.5% to $229.68.</li>
<li>The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 1.2%; the Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1.7%.</li>
</ul>
<h2 class="wp-block-heading">Friday&#8217;s Stock Movers</h2>
<ul>
<li>Stocks reacting to earning reports included:
<ul>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), up 0.72%</li>
<li>Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) up 0.80%</li>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) up 0.17% </li>
<li>KLA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) up 2.11%, </li>
<li>PPG Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) down 6.12%, </li>
<li>ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) down 6.36%, </li>
<li>Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) up 5.52%, </li>
<li>Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) down 16.5%,</li>
<li>LPL Financial Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) up 1.99%.</li>
<li>Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>): down 1.31%</li>
<li>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>): up 6.7%</li>
<li>Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>): down 3.7%</li>
<li>Colgate-Palmolive Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>): down 4.5%</li>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>): down 0.8%</li>
<li>Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>): up 3.6%</li>
<li>Booz Allen Hamilton Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>): down 0.6%</li>
</ul>
</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43398182/trumps-25-tariffs-could-slaughter-canada-mexico-economies-hit-us-auto-industry-analysts-warn">Trump&#8217;s 25% Tariffs Could Slaughter Canada, Mexico Economies, Hit US Auto Industry, Analysts Warn</a></li>
</ul>
Photo: Shutterstock

Earnings

Equities

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Tech

ETFs

$BTC

AAPL

ABBV

AMZN

CHTR

DECK

SPDR Dow Jones Industrial Average ETF Trust

INTC

KLAC

LPLA

MAGS

NVDA

TSLA

Tech Stocks Rally, S&P 500 Flirts With Records, Gold Extends All-Time Highs: What's Driving Markets Friday?

ResMed shares are trading lower. The company reported Q2 financial results.

Keybanc analyst Brett Fishbin maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Overweight and raises the price target from $266 to $280.

Keybanc Maintains Overweight on ResMed, Raises Price Target to $280

Piper Sandler analyst Adam Maeder maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Neutral and raises the price target from $252 to $260.

Piper Sandler Maintains Neutral on ResMed, Raises Price Target to $260

Needham analyst Mike Matson reiterates ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on ResMedto Hold

ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) reported its Q2 earnings results on Thursday, January 30, 2025 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
ResMed beat estimated earnings by 5.0%, reporting an EPS of $2.43 versus an estimate of $2.31.
Revenue was up $119.00 million from the same period last year.
<h3>Earnings History Overview</h3>
The company beat on EPS by $0.16 in the previous quarter, leading to a 7.000000000000001% increase share price change the next day.
Here's a look at ResMed's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.04</td>
<td>2.06</td>
<td>1.91</td>
<td>1.79</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.20</td>
<td>2.08</td>
<td>2.13</td>
<td>1.88</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.18B</td>
<td>1.19B</td>
<td>1.17B</td>
<td>1.15B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.23B</td>
<td>1.22B</td>
<td>1.20B</td>
<td>1.16B</td>
</tr>
</tbody>
</table>

To track all earnings releases for ResMed <a href="https://www.benzinga.com/quote/RMD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: ResMed Q2

The Q2 earnings report for ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) was released on Thursday, January 30, 2025 at 04:05 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
ResMed beat estimated earnings by 5.0%, reporting an EPS of $2.43 versus an estimate of $2.31.
Revenue was up $119.00 million from the same period last year.
<h3>Past Earnings Performance</h3>
During the previous quarter, the company beat on EPS by $0.16, leading to a 7.000000000000001% increase share price change the next day.
Here's a look at ResMed's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.04</td>
<td>2.06</td>
<td>1.91</td>
<td>1.79</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.20</td>
<td>2.08</td>
<td>2.13</td>
<td>1.88</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.18B</td>
<td>1.19B</td>
<td>1.17B</td>
<td>1.15B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.23B</td>
<td>1.22B</td>
<td>1.20B</td>
<td>1.16B</td>
</tr>
</tbody>
</table>

To track all earnings releases for ResMed <a href="https://www.benzinga.com/quote/RMD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ResMed Earnings Analysis: Q2 Recap

ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) reported quarterly earnings of $2.43 per share which beat the analyst consensus estimate of $2.32 by 4.74 percent. This is a 29.26 percent increase over earnings of $1.88 per share from the same period last year. The company reported quarterly sales of $1.28 billion which beat the analyst consensus estimate of $1.27 billion by 1.15 percent. This is a 10.23 percent increase over sales of $1.16 billion the same period last year.

Earnings Beats

ResMed Q2 2025 Adj EPS $2.43 Beats $2.32 Estimate, Sales $1.28B Beat $1.27B Estimate

Wall Street is struggling to find risk-on momentum, with major indexes stuck near the flatline at midday as investors assess the latest earnings reports from mega-cap tech stocks and weaker-than-expected U.S. economic growth in the<a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43336153/us-economy-grows-below-q4-estimates-as-consumer-spending-hits-7-quarter-high"> final quarter of 2024.</a>
After Tuesday's rally — which followed a selloff triggered by DeepSeek&#8217;s impact earlier in the week — caution has taken hold, signaling the wounds from the downturn are still fresh.
Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>) is among the hardest-hit stocks, plunging more than 6%, which could mark its worst daily decline<a href="https://www.benzinga.com/news/earnings/25/01/43333060/msft-stock-declines-over-4-in-premarket-after-q2-results-ceo-satya-nadella-says-deepseek-has-some-r"> since October 2022</a>.
Despite reporting overall stronger-than-expected earnings, Microsoft&#8217;s cloud segment, Azure, fell short of growth expectations, and the company slightly missed its revenue guidance for the ongoing quarter.
In contrast, Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) climbed 1.7% post-earnings, reaching new all-time highs.
Another major laggard was United Parcel Service Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>), which plummeted 15%, potentially heading for its worst single-day drop <a href="https://www.benzinga.com/news/earnings/25/01/43335015/ups-q4-earnings-major-customer-volume-cut-raises-jitters-stock-tanks">since going public in 2002</a>.
UPS Chief Financial Officer Brian Dykes revealed during the earnings call the company reached an agreement in principle with Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) to significantly cut the volume of packages it handles for the e-commerce giant, aiming for a 50% reduction by the second half of 2026.
The U.S. dollar and bond yields remained stable following the Federal Reserve's decision Wednesday to keep interest rates unchanged at 4.25%-4.5%.
Among commodities, precious metals stood out, with gold rising 1.4% to <a href="https://www.benzinga.com/news/econ-s/25/01/43348204/gold-hits-record-high-as-central-banks-ease-stance-5-mining-stocks-rally">new all-time highs </a>and silver climbing 2.4%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) edged up 1% to around $105,000.
<h3 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>• Russell 2000</td>
<td>2,306.29</td>
<td>1.0%</td>
</tr>
<tr>
<td>• Dow Jones</td>
<td>44,866.30</td>
<td>0.3%</td>
</tr>
<tr>
<td>• S&amp;P 500</td>
<td>6,054.43</td>
<td>0.3%</td>
</tr>
<tr>
<td>• Nasdaq 100</td>
<td>21,420.81</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:50 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012925&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;inched 0.2% higher to $603.10.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) edged up by 0.2% to $448.22.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;edged 0.1% lower to $521.30.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.2% to $228.50.</li>
<li>The&nbsp;Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, up 1.7%; the&nbsp;Technology Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>), lagged down 0.4%.</li>
</ul>
<h3 class="wp-block-heading">Thursday&#8217;s Stock Movers</h3>
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose 4.4% in reaction to quarterly earnings results. </li>
<li>Other stocks reacting to earnings include:
<ul>
<li>ServiceNow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) down 12.6%</li>
<li>International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) up 12.3%</li>
<li>Lam Research Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) up 7.96%</li>
<li>Raymond James Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) down 1.15%</li>
<li>Ameriprise Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) down 3.08%</li>
<li>Waste Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) up 4.53%</li>
<li>Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) up 10.4%</li>
<li>Lazard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) up 3.58%</li>
<li>Kirby Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEX#NYSE">KEX</a>) up 7.22%</li>
<li>Flagstar Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLG#NYSE">FLG</a>) up 16.46%</li>
<li>Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) down 4.43%</li>
<li>Northrop Grumman Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) down 2.04%</li>
<li>Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) down 6.09%</li>
<li>Valero Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) down 2.5%, </li>
<li>Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) down 8.46%,</li>
</ul>
</li>
<li>Major companies slated to report earnings after the close are Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), KLA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>), PPG Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>), ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) and LPL Financial Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>). </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/25/01/43342224/ryan-cohen-moves-gamestop-shares-to-personal-name-sparking-speculation-on-next-steps">Ryan Cohen Moves 36.8 Million GameStop Shares To Personal Name, Sparking Speculation On Next Steps</a></li>
</ul>
Photo via Shutterstock.

Markets

Movers

LRCX

MSFT

Wall Street Remains Flat, Microsoft Eyes Heaviest Drop Since Late 2022, Gold Sets Fresh Records: What's Driving Markets Thursday?

ABCB

ALGM

APPF

Adtalem Global Education Inc. Common Stock

ATGE

BAFN

BBVA

BHLB

BOOT

CACC

CHKP

CIVB

CMCSA

CNOB

COUR

CSWI

CVCO

FBIZ

FCFS

FFWM

FINW

FISI

FLWS

FRME

GSIT

KRNY

MBLY

MBUU

NTCT

ONEW

PFSI

REAL

SCSC

SHEL

SILC

SIRI

SKYW

STBA

STEL

Earnings Scheduled For January 30, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Citigroup analyst Jason Bazinet initiated coverage on News Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWSA#NASDAQ">NWSA</a>) with a Buy rating and announced a price target of $36. News shares closed at $27.47 on Wednesday. See how other analysts view this stock.</li>
<li>Wells Fargo initiated coverage on Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with an Equal-Weight rating and announced a price target of $47. Maplebear shares closed at $44.82 on Wednesday. See how other analysts view this stock.</li>
<li>UBS analyst Manav Gupta initiated coverage on Tyson Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) with a Neutral rating and announced a price target of $62. Tyson Foods shares closed at $55.46 on Wednesday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Adam Maeder initiated coverage on ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Neutral rating and announced a price target of $252. ResMed shares closed at $236.17 on Wednesday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark analyst Mike Hickey initiated coverage on AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy rating and announced a price target of $375. AppLovin shares closed at $329.20 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying APP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10124356/image-60-1024x591.png" alt="" class="wp-image-728673" style="width:565px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10124356/image-60-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10124356/image-60-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10124356/image-60-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10124356/image-60.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42917071/top-2-health-care-stocks-that-are-ticking-portfolio-bombs-2">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Initiation

CART

NWSA

This AppLovin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

In the latest quarter, 5 analysts provided ratings for ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $256.6, a high estimate of $283.00, and a low estimate of $232.00. This upward trend is evident, with the current average reflecting a 1.96% increase from the previous average price target of $251.67.
<img src="https://www.benzinga.com/files/images/story/2025/1736514077_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of ResMed by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$252.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Announces</td>
<td>Hold</td>
<td>$250.00</td>
<td>-</td>
</tr>
<tr>
<td>Craig Wong-Pan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$232.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$266.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$283.00</td>
<td>$280.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ResMed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ResMed compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of ResMed's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RMD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ResMed analyst ratings.</a>
<h2>About ResMed</h2>
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
<h3>ResMed: Delving into Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: ResMed's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 11.08%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 25.43%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.19%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): ResMed's ROA excels beyond industry benchmarks, reaching 4.42%. This signifies efficient management of assets and strong financial health.
Debt Management: ResMed's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.16.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 5 Analyst Ratings Have To Say About ResMed

Press Releases

ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025

Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

Jan De Witte joins GHO Capital as Operating Partner

ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

General

Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution

New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US

Comments

ResMed

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO